Beyond the horizon: Immune checkpoint inhibitors reshaping the landscape of urothelial cancer

Beyond the horizon: Immune checkpoint inhibitors reshaping the landscape of urothelial cancer

Saved in:

Bibliographic Details
Main Author:	Ojas Patel
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-10-01
Series:	Indian Journal of Urology
Online Access:	https://journals.lww.com/10.4103/iju.iju_51_24
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)
by: K. V. Menshikov, et al.
Published: (2022-10-01)

Impact of Antibiotics on the Efficacy of Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
by: Do Gyeong Lim, et al.
Published: (2023-12-01)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
by: Julie M. Shabto, et al.
Published: (2020-04-01)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
by: Fu-Shun Hsu, et al.
Published: (2017-01-01)

Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy
by: Olivia Le Saux, et al.
Published: (2025-08-01)

Immune checkpoint inhibitors in high‐grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation
by: Mahmoud Khalil, et al.
Published: (2024-05-01)

Application of Immune Checkpoint Inhibitors in Cancer
by: Zhijun Chen, et al.
Published: (2025-08-01)

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
by: Albert Jang, et al.
Published: (2023-12-01)

Combining immune checkpoints with TNFSF agonists: a new horizon for cancer and autoimmune therapies
by: Lele Sun, et al.
Published: (2025-03-01)

Immune-checkpoint inhibitor resistance in patients with cancer
by: Luis Cabezón-Gutiérrez, et al.
Published: (2025-05-01)

Role of tumor mutational burden in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Zhe Wang, et al.
Published: (2025-05-01)

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study
by: Rossanna C Pezo, et al.
Published: (2024-03-01)

Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors
by: Liang-Yun Cheng, et al.
Published: (2024-12-01)

Unleashing immunity against oral cancer with immune checkpoint inhibitors
by: Ajay Guru
Published: (2024-06-01)

Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
by: Ya Guo, et al.
Published: (2022-01-01)

Negative Immune Checkpoint Inhibitors
by: Magda Drewniak-Świtalska, et al.
Published: (2025-05-01)

Research progress of immune checkpoint inhibitors in ovarian cancer
by: Lingli Zhao, et al.
Published: (2024-12-01)

The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
by: Nora Chokr, et al.
Published: (2018-01-01)

Beyond the Limits: How Is Spectral Flow Cytometry Reshaping the Clinical Landscape and What Is Coming Next?
by: Kamila Czechowska, et al.
Published: (2025-06-01)

Prognostic significance of circulating tumor DNA in urothelial carcinoma patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis
by: Qingping Ma, et al.
Published: (2025-04-01)

Combining JAK Inhibitors with Immune Checkpoint Inhibitors: Overcoming Resistance in Cancer Treatment
by: Hai‐Jing Zhong
Published: (2025-03-01)

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
by: Jing Wei, et al.
Published: (2024-12-01)

Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
by: Jie Yao, et al.
Published: (2024-12-01)

Immune checkpoint inhibitor-related myocarditis in patients with lung cancer
by: Wenli Cao, et al.
Published: (2025-04-01)

Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer
by: A. A. Izmailov, et al.
Published: (2023-09-01)

Hepatotoxicity induced by immune checkpoint inhibitors
by: Flaviu Muresan, et al.
Published: (2024-10-01)

Pouchitis After Immune Checkpoint Inhibitors
by: Gabriel Sperling, et al.
Published: (2023-08-01)

Chronic immune checkpoint inhibitor pneumonitis
by: Julie R Brahmer, et al.
Published: (2020-05-01)

Adverse reactions of immune checkpoint inhibitors
by: E. R. Zagidullina, et al.
Published: (2025-06-01)

Immune Checkpoint Inhibitors in the Treatment of Lymphomas
by: KV Lepik
Published: (2018-10-01)

New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine
by: RuiXin Zheng, et al.
Published: (2025-09-01)

Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma
by: Grant A McArthur, et al.
Published: (2025-05-01)

Immune checkpoint inhibitors in metastatic colorectal cancer therapy (a review)
by: P. P. Sorochan, et al.
Published: (2022-07-01)

Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives
by: Vikrant Rai
Published: (2025-05-01)

Immune checkpoint Inhibitor-Induced Autoimmune hemolytic anemia in endometrial cancer
by: Michael Danziger, et al.
Published: (2025-06-01)

Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer
by: Corti C, et al.
Published: (2025-04-01)

Immunotherapeutic Potential of Lactobacillus Species as Immune Checkpoint Inhibitors in Cancer Immunotherapy
by: Renukadevi J, et al.
Published: (2025-01-01)

Highlights on immune checkpoint inhibitors in non–small cell lung cancer
by: Meng Shen, et al.
Published: (2017-03-01)

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
by: Jiayuan Le, et al.
Published: (2025-12-01)

Nanomaterials and immune checkpoint inhibitors in cancer immunotherapy: the synergistic innovation prospects
by: Jing Chen, et al.
Published: (2025-06-01)